TABLE 1.
Adjusted/weighted and unadjusted/unweighted patient and tumor characteristics of the SEER-Medicare database study, by delay interval.
| Characteristic | Adjusted % (Unadjusted %)* unless otherwise specified | ||||
|---|---|---|---|---|---|
| ≤30 days | 31–60 days | 61–90 days | 91–120 days | 121–180 days | |
| Total Patients | 73,491 | 17,345 | 2,586 | 686 | 436 |
| Mean age in years | 75.2 (75.1) | 75.2 (75.3) | 75.1 (75.7) | 75.5 (75.9) | 75.3 (77.2) |
| Gender | |||||
| Female | 99.2 (99.1) | 99.1 (99.3) | ** | ** | ** |
| Male | 1.0 (0.9) | 1.0 (0.7) | ** | ** | ** |
| Race/Ethnicity | |||||
| White | 89.3 (90.2) | 89.1 (86.9) | 89.1 (83.3) | 88.3 (77.1) | 87.9 (75.9) |
| Black | 6.3 (5.5) | 6.5 (8.2) | 6.8 (11.3) | 5.9 (16.3) | 7.6 (18.1) |
| Asian | 1.9 (1.8) | 1.8 (2.0) | 1.8 (2.3) | 2.3 (2.0) | 1.2 (2.3) |
| Hispanic | 1.0 (0.9) | 1.0 (1.2) | 1.0 (1.7) | 1.3 (1.9) | 0.9 (2.3) |
| Other/Unknown | 1.6 (1.5) | 1.6 (1.7) | 1.2 (1.4) | 2.6 (1.8) | 1.4 (2.1) |
| Mean Charlson Comorbidity | 0.5 (0.5) | 0.5 (0.6) | 0.5 (0.7) | 0.5 (0.8) | 0.5 (0.8) |
| Setting§ | |||||
| Large metropolitan | 54.6 (51.5) | 54.5 (64.6) | 53.2 (67.1) | 50.4 (67.5) | 56.1 (69.0) |
| Metropolitan | 29.1 (30.5) | 28.7 (24.3) | 28.6 (22.9) | 33.2 (21.8) | 26.5 (23.2) |
| Urban | 6.0 (6.6) | 6.3 (4.4) | 7.1 (4.3) | 6.2 (3.8) | 3.7 (2.3) |
| Less Urban/Rural | 10.3 (11.4) | 10.5 (6.7) | 11.1 (5.8) | 10.3 (7.0) | 13.8 (5.5) |
| Region¶ | |||||
| Northeast | 17.4 (16.0) | 17.7 (22.2) | 17.3 (22.2) | 18.0 (23.3) | 18.9 (22.9) |
| South | 20.8 (22.4) | 20.4 (15.2) | 21.0 (13.5) | 19.2 (13.6) | 18.4 (18.4) |
| Midwest | 18.5 (19.3) | 19.0 (15.8) | 19.1 (14.2) | 19.5 (14.6) | 14.9 (12.4) |
| West | 43.3 (42.3) | 42.9 (46.8) | 42.6 (50.1) | 43.3 (48.5) | 47.9 (46.3) |
| Invasive Histology | |||||
| Ductal | 86.6 (86.9) | 86.4 (85.9) | 86.1 (85.6) | 85.8 (85.6) | 87.1 (82.3) |
| Lobular | 10.9 (10.6) | 11.0 (11.9) | 10.7 (11.9) | 11.5 (12.0) | 11.6 (14.5) |
| Other/unknown | 2.5 (2.6) | 2.6 (2.3) | 3.3 (2.5) | 2.7 (2.5) | 1.3 (3.2) |
| Grade | |||||
| Well differentiated | 22.2 (21.8) | 22.5 (24.1) | 22.2 (23.0) | 21.3 (20.4) | 17.3 (20.2) |
| Moderately differentiated | 41.8 (41.3) | 42.1 (43.2) | 40.4 (43.2) | 43.6 (43.6) | 44.5 (42.4) |
| Poorly differentiated | 25.2 (25.6) | 24.6 (23.7) | 26.0 (24.3) | 26.0 (24.8) | 28.7 (24.5) |
| Undifferentiated/Anaplastic | 1.3 (1.4) | 1.2 (1.0) | 1.3 (1.0) | 1.0 (1.8) | 1.6 (2.3) |
| Unknown | 9.5 (9.9) | 9.7 (8.0) | 10.2 (8.6) | 8.1 (9.5) | 7.9 (10.6) |
| Mean tumor size in mm | 19.1 (19.2) | 18.9 (18.3) | 19.5 (20.1) | 20.0 (21.6) | 20.4 (26.3) |
| AJCC Stage‡ | |||||
| I | 57.9 (57.8) | 58.4 (59.3) | 56.8 (55.2) | 50.9 (55.3) | 56.2 (44.0) |
| II | 35.9 (36.2) | 35.6 (34.5) | 37.2 (36.2) | 42.6 (33.8) | 37.4 (39.5) |
| III | 6.2 (6.0) | 6.1 (6.2) | 6.0 (8.6) | 6.4 (10.9) | 6.5 (16.5) |
| Median Income (Census Tract, $) | 50,363 (49,728) | 50,312 (52,882) | 49,735 (51,649) | 49,990 (26,805) | 49,549 (21,076) |
| % of Persons 25+ Years Old Having < High School (12 years) Education by Census Tract | |||||
| 17.6 (17.6) | 17.6 (17.2) | 18.0 (18.4) | 17.5 (20.4) | 18.5 (19.5) | |
| Mean Year of Diagnosis | 2002.3 (2001.8) | 2002.3 (2004.0) | 2002.4 (2004.5) | 2002.3 (2004.2) | 2002.2 (2004.3) |
| Marital Status | |||||
| Married | 45.5 (46.7) | 45.0 (42.9) | 46.6 (36.9) | 46.7 (33.5) | 41.6 (31.0) |
| Not Married | 54.5 (53.3) | 55.0 (57.1) | 53.4 (63.1) | 53.3 (66.5) | 58.4 (69.0) |
| Mean Breast Cancer Sequence** | |||||
| 1.1 (1.1) | 1.1 (1.1) | 1.1 (1.1) | 1.1 (1.1) | 1.1 (1.1) | |
| Mean Elixhauser Score | 1.1 (1.0) | 1.1 (1.1) | 1.1 (1.5) | 1.5 (1.7) | 1.0 (1.6) |
| Mean # Nodes Positive | 1.0 (1.0) | 1.0 (0.9) | 0.9 (1.1) | 1.0 (1.2) | 1.1 (1.5) |
| Mean # Nodes Examined | 8.9 (9.3) | 8.8 (7.6) | 8.7 (7.3) | 8.7 (7.3) | 8.0 (7.1) |
| Surgery Type | |||||
| Breast Conservation | 72.7 (73.6) | 73.3 (69.9) | 73.2 (68.7) | 74.6 (64.4) | 72.2 (63.5) |
| Mastectomy | 27.3 (26.4) | 26.7 (30.1) | 26.8 (31.3) | 25.4 (35.6) | 27.8 (36.5) |
| Chemotherapy Use | |||||
| Yes | 22.5 (23.0) | 21.9 (21.6) | 24.7 (18.2) | 21.1 (18.5) | 26.5 (15.6) |
| No | 77.5 (77.0) | 78.0 (78.4) | 75.3 (81.8) | 78.9 (81.5) | 73.5 (84.4) |
| Radiotherapy Use | |||||
| Yes | 50.9 (50.9) | 51.0 (52.7) | 51.8 (44.8) | 55.4 (38.5) | 49.0 (41.7) |
| No | 49.1 (49.1) | 49.0 (47.3) | 46.2 (55.2) | 44.6 (61.5) | 51.0 (58.3) |
Totals may vary from 100% due to rounding.
Cells have been deleted as per SEER Medicare requirements to censor cells containing <11 individuals, or other cells that make such cells calculable.
Setting definitions: Large metropolitan = counties of metropolitan areas of ≥1,000,000; metropolitan = counties in metropolitan areas of <250,000–1,000,000; urban = urban population of ≥20,000 adjacent or nonadjacent to a metropolitan area; less urban = urban population of 2,500–19,999 adjacent or nonadjacent to a metropolitan area; rural = completely rural or <2,500 urban population, adjacent or nonadjacent to a metropolitan area.
Region groupings: Northeast = Connecticut and New Jersey registries; South = Atlanta, Kentucky, and Louisiana registries; Midwest = Detroit and Iowa registries; West = Hawaii, New Mexico, Seattle, Utah, and California registries. Registries were adjusted individually, but are grouped for reporting purposes.
AJCC Stage: 3rd and 6th editions were combined. Substages (e.g. IIA, IIB) were collapsed to minimize differences between these AJCC Editions.
The number of the cancer, when a patient has one or more distinct primary cancers during their lifetime.